In a patient with markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and a low blood urea nitrogen (BUN) to creatinine ratio, and a normal computed tomography (CT) scan of the abdomen and pelvis, what is the next appropriate management step?

Next Management Step for Elevated Transaminases with Normal CT

The next appropriate action is to obtain a comprehensive hepatitis panel (hepatitis A, B, C, E, and cytomegalovirus), complete medication/supplement history with immediate discontinuation of any hepatotoxic agents, alcohol assessment, metabolic syndrome evaluation, and abdominal ultrasound to evaluate for fatty liver disease 1.

Understanding the Clinical Picture

This patient presents with moderate transaminase elevation (AST 181, ALT 132 - approximately 4-5 times the upper limit of normal assuming normal range ~40 U/L) with a hepatocellular pattern of injury 1. The low BUN/creatinine ratio of 8 (normal 10-20) suggests adequate hydration or potentially increased protein catabolism, but is not the primary concern here.

The normal CT abdomen/pelvis has ruled out:

• Biliary obstruction
• Liver masses or metastases
• Gross structural abnormalities
• Acute vascular events (though CT may miss early Budd-Chiari)

Immediate Diagnostic Workup

Core Laboratory Panel 1, 2

Essential first-line tests:

• Viral hepatitis serologies: HBsAg, anti-HBc, anti-HCV, hepatitis A IgM, hepatitis E IgM (particularly if ALT rises >1000 U/L) 2
• Autoimmune markers: ANA, ASMA, anti-LKM, immunoglobulin G levels 1
• Metabolic screen: Fasting glucose, lipid panel, hemoglobin A1c
• Iron studies: Ferritin, transferrin saturation (>45% suggests hemochromatosis) 2
• Additional liver function: Total and direct bilirubin, alkaline phosphatase, GGT, albumin, PT/INR 1, 3
• Creatine kinase (CK): To exclude rhabdomyolysis as source of AST elevation 1, 4

Critical History Elements 2

Medication review - specifically ask about:

• All prescription medications (statins, antibiotics, antifungals, NSAIDs)
• Over-the-counter medications (acetaminophen, herbal supplements)
• Recent medication changes in past 3 months

Alcohol quantification - use AUDIT-C screening:

• Current weekly units
• Pattern of consumption
• AST:ALT ratio >2 suggests alcoholic liver disease 1

Metabolic risk factors:

• BMI, waist circumference
• Diabetes, hypertension, dyslipidemia
• AST:ALT ratio <1 suggests NAFLD 1

Exposure history:

• Travel to hepatitis-endemic areas
• Tattoos, piercings, injection drug use
• Sexual contacts, blood transfusions

Imaging Strategy

Abdominal Ultrasound - First-Line 1

Ultrasound is the appropriate initial imaging despite the normal CT because:

• Detects hepatic steatosis with 84.8% sensitivity for moderate-severe fatty infiltration (>30%) 1
• Evaluates liver echogenicity and size
• Assesses for cirrhosis features
• No radiation exposure
• Cost-effective

The CT was appropriate to rule out structural lesions but ultrasound is superior for detecting fatty liver disease, the most common cause of mild-moderate transaminase elevation in developed countries (20-30% general population prevalence) 1.

Differential Diagnosis Priority

Based on the hepatocellular pattern with moderate elevation 1:

Most Common (>80% of cases):

1. Nonalcoholic fatty liver disease (NAFLD) - especially if metabolic syndrome present
2. Alcohol-induced liver disease - if significant consumption
3. Drug-induced liver injury - review all medications/supplements

Uncommon but Important: 4. Chronic hepatitis B or C 5. Hemochromatosis 6. Autoimmune hepatitis

Rare but Treatable: 7. Wilson disease (if age <40) 8. Alpha-1 antitrypsin deficiency

Consider if AST disproportionately elevated:

• Macro-AST (benign immunoglobulin-AST complex) 5, 6
• Rhabdomyolysis (check CK) 4
• Cardiac or skeletal muscle injury 1

Management Algorithm

If Viral Hepatitis Identified:

• Hepatitis B (HBsAg+): Check HBV DNA, HBeAg, refer to hepatology 3
• Hepatitis C (anti-HCV+): Confirm with HCV RNA, refer for direct-acting antivirals 7

If Drug-Induced Suspected:

• Immediately discontinue suspected hepatotoxic agent 8, 2
• Recheck transaminases in 3-5 days - expect 50% decline if drug-related 9
• If no improvement or worsening, consider other etiologies

If Autoimmune Hepatitis Suspected:

• Elevated IgG (>1.5x ULN) with positive autoantibodies warrants hepatology referral 2

If Metabolic/Fatty Liver Disease:

• Lifestyle modification: Weight loss 7-10%, Mediterranean diet, 150 min/week moderate exercise
• Optimize metabolic comorbidities
• Avoid alcohol completely
• Consider fibrosis assessment with FIB-4 or APRI score 10

Critical Red Flags Requiring Urgent Action

Immediate hepatology referral if 8, 2:

• Bilirubin >3x ULN
• INR >1.5
• Albumin <3.5 g/dL
• Platelet count <150,000
• Any signs of hepatic decompensation (ascites, encephalopathy, variceal bleeding)

Common Pitfalls to Avoid

1. Don't simply repeat the same tests - 84% remain abnormal at 1 month, 75% at 2 years 2
2. Don't assume normal CT excludes all pathology - fatty liver and early fibrosis require ultrasound
3. Don't overlook macro-AST - if isolated AST elevation persists despite negative workup, perform PEG precipitation test 5, 6
4. Don't forget to check CK - rhabdomyolysis can present with isolated transaminase elevation 1, 4
5. Isolated elevated ferritin ≠ hemochromatosis - common in NAFLD and alcohol excess; requires transferrin saturation >45% 2

Monitoring Strategy

• Recheck liver enzymes in 1-2 weeks after initial workup and interventions 8
• If improving (>50% decline), continue current management
• If stable or worsening, proceed to extended panel and consider hepatology referral 2
• Liver biopsy reserved for: unclear diagnosis after full workup, suspicion of multiple etiologies, or need to stage fibrosis when non-invasive methods inadequate 7, 3